Biocardia Lifesciences Financing
Biocardia Lifesciences, Inc., Corporation just filed form D about $6.50 million debt financing. This is a new filing. Biocardia Lifesciences was able to fundraise $4.37 million so far. That is 67.29% of the financing round. The total offering amount was $6.50 million. The financing form was filed on 2016-10-31. The reason for the financing was: The Issuer will not be selling the remaining $2,126,375 worth of securities.. The fundraising still has about $2.13 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Biocardia Lifesciences is based in California. The filler’s business is Other Health Care. The form was signed by David McClung Vice President Finance. The company was incorporated more than five years ago. The filler’s address is: 125 Shoreway Road, Suite B, San Carlos, Ca, California, 94070. Peter Altman is the related person in the form and it has address: 125 Shoreway Road, Suite B, San Carlos, Ca, California, 94070. Link to Biocardia Lifesciences Filing: 000163588616000003.
Analysis of Biocardia Lifesciences Offering
On average, firms in the Other Health Care sector, sell 68.60% of the total offering size. Biocardia Lifesciences sold 67.29% of the offering. The fundraising is still open. The average fundraising amount for companies in the Other Health Care industry is $1.16 million. The total amount raised is 277.04% bigger than the average for companies in the Other Health Care sector. The minimum investment for this offering was set at $0. If you know more about the reasons for the fundraising, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Biocardia Lifesciences Also
The Form D signed by David McClung might help Biocardia Lifesciences, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.